Moderna shares surged 177% in a single session on Wednesday after announcing positive results for its personalized mRNA cancer vaccine developed with Merck in a Phase 3 melanoma trial. The American biotech gained approximately $30 billion in market value in one day. This spectacular move was driven by heavy short covering. The article identifies three other American stocks showing a similar technical setup that could replicate this type of performance.
Source: Read the original article
